Clearside Biomedical, Inc.
Industry: Tissue-targeting ophthalmic therapeutics
Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.
Clearside’s patented microinjection dosage form is the only non-surgical method for focal administration of drugs to the retina and choroid through the suprachoroidal space (SCS™). As of early 2016, the company had products in Phase 2 and Phase 3 clinical trials and is developing additional therapies through collaborations with third parties.
An estimated 5 million Americans suffer from the various back-of-the-eye diseases that Clearside targets – namely, macular edema, non-infectious uveitis and wet AMD.
Company website: Clearside Biomedical, Inc.
